Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood

Immunopharmacology

Volumn 46, Issue 2, 2000, Pages 175-179

  Shannon, E ^a,b   Aseffa, A ^a,b   Pankey, G ^a,b   Sandoval, F ^a,b   Lutz, B ^a,b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

HIV infected patients; Interleukin 2; Thalidomide; TNF

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; STAPHYLOCOCCUS ENTEROTOXIN A; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; APHTHOUS ULCER; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ERYTHEMA NODOSUM LEPROSUM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SUPERNATANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033959816     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00169-1     Document Type: Article

References (20)

1. Bunk S. New weapon attacks latent HIV reservoirs. The Scientist. 12(24):1998.
2. Carlson R., Fishcher H., Sjogren H.O. Binding of staphylococcal enterotoxin A to accessory cells is a requirement for its ability to activate human T cells. J. Immunol. 40:1989;2484.
3. Eriksson, T., 1997. Pharmacokinetics of the Enantiomers of Thalidomide. PhD Thesis, Studentlitteratur's Printing Office, Lund, Sweden.
4. Fernandez L.P., Schlegel P.G., Baker J., Chen Y., Chao N.J. Does thalidomide affect IL-2 response and production? Exp. Hematol. 23:1995;978-985.
5. Haslett P., Hempstead C., Seidman J., Diakun D., Vesquez V., Freeman H., Kaplan G. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res. Hum. Retroviruses. 13:1997;1047-1053.
6. Haslett P., Corral L., Albert M., Kaplan G. Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187(11):1998;1885-1892.
7. Jacobson J.M., Greenspan J.S., Spritzler J., Ketter N., Fahey J.L., Jackson J., Fox L., Chernoff M., Wu A.W., MacPhail L.A., Vasquez G.J., Wohl D.A. Thalidomide for the treatment of oral aphthous ulcers in patients with immunodeficiency virus infection. N. Engl. J. Med. 336(21):1997;1487-1493.
8. Kroemer G., Andreu J.L., Gonzalo A.G., Gutierrez-Romoa J.C., Martinez A. Interleukin-2, autotolerance, and autoimmunity. Adv. Immunol. 2(50):1992;147-235.
9. McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M., Ewan P.W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits TH1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. 99:1995;160-167.
10. + T lymphocytes. J. Immunol. 129(3):1982;1076-1079.
11. Öyvind Ö., Riesbeck K., Qi Z., Eriksson T., Schustz H., Ekberg H. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory function in vitro. Transplant Immunology. 4:1996;117-125.
12. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits TNF-α production by stimulated human monocytes. J. Exp. Med. 173:1991;699-703.
13. Sampaio E.P., Kaplan G., Miranda A., Nery J.A.C., Miguel C.P., Viana S.M., Sarno E.N. The influence of thalidomide on clinical leprosum. J. Infect. Dis. 168:1993;408-414.
14. Shannon E.J., Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 31:1995;109-116.
15. Shannon E.J., Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS-evoked synthesis of TNF-α by mononuclear cells. Immunopharmacology and Immunotoxicology. 18(1):1996;59-72.
16. Shannon E.J., Sandoval F., Krahenbuhl J.L. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α Immunopharmacology. 36:1997;9-15.
17. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years experience of thalidomide. Int. J. Dermatol. 19:1980;318-322.
18. Youle M., Clarbour J., Farthing C., Connolly M., Hawkins D., Staughton R., Gazzard B. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br. Med. J. 298:1989;432-433.
19. Zanussi S., Simonelli C., D'Andrea M., Caffau C., Clerici M., Tirelli U., de Paoli P. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin. Exp. Immunol. 105:1996;220-224.
20. Zwingenberger K., Wnendt S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflammation. 46:1996;177-211.